| Literature DB >> 25221547 |
Bruno Veigas1, Alexandra R Fernandes2, Pedro V Baptista3.
Abstract
The increasing levels of drug resistance are one of biggest threats to overcome microbial infection. The ability to rapidly and accurately detect a given pathogen and its drug resistance profile is essential for the appropriate treatment of patients and for preventing further spread of drug-resistant strains. The predictive and informative value of these molecular markers needs to be translated into robust surveillance tools that correlate to the target and extent of resistance, monitor multiresistance and provide real time assessment at point-of-need. Rapid molecular assays for the detection of drug-resistance signatures in clinical specimens are based on the detection of specific nucleotide sequences and/or mutations within pre-selected biomarkers in the genome, indicative of the presence of the pathogen and/or associated with drug resistance. DNA and/or RNA based assays offer advantages over phenotypic assays, such as specificity and time from collection to result. Nanotechnology has provided new and robust tools for the detection of pathogens and more crucially to the fast and sensitive characterisation of molecular signatures of drug resistance. Amongst the plethora of nanotechnology based approaches, gold nanoparticles have prompt for the development of new strategies and platforms capable to provide valuable data at point-of-need with increased versatility but reduced costs. Gold nanoparticles, due to their unique spectral, optical and electrochemical properties, are one of the most widely used nanotechnology systems for molecular diagnostics. This review will focus on the use of gold nanoparticles for screening molecular signatures of drug resistance that have been reported thus far, and provide a critical evaluation of current and future developments of these technologies assisting pathogen identification and characterisation.Entities:
Keywords: AuNPs; Tuberculosis; gold nanoparticles; molecular diagnostics technologies; multidrug resistance; nanodiagnostics; nanotechnology
Year: 2014 PMID: 25221547 PMCID: PMC4147832 DOI: 10.3389/fmicb.2014.00455
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
AuNPs-based systems for pathogen antibiotic susceptibility characterization.
| Application | Description | Target(s) | Reference(s) |
|---|---|---|---|
| Colorimetric detection of AuNPs spotted onto an illuminated glass waveguide Detection relies on the evaluation of SPR change upon target hybridization | Detection of | ||
| Antibiotic susceptibility characterization | Colorimetric detection with AuNPs. Detection relies on the evaluation of SPR change upon aggregation and the concomitant colorimetric changes that can be assessed by the naked eye | Detection of | |
| Colorimetric detection with AuNPs. Detection relies on the evaluation of SPR change upon aggregation. Sandwich hybridization assay, AuNPs act as SPR signal enhancers | Detection of |
AuNPs-based systems for pathogen antibiotic susceptibility characterization, preclinical/clinical metadata of sensitivity and specificity.
| Pathogen | Target | Sensitivity | Specificity | No. of isolates | Reference |
|---|---|---|---|---|---|
| MRSA | Detection of mecA gene associated with methicillin resistance, in S. aureus. Genomic DNA samples isolated from cultured bacterial cells | Analytical sensitivity of 66 pg/μl of MRSA total genomic DNA | n.d. | n.d. | |
| Detection of mecA gene associated with methicillin resistance, in S. aureus. Validation with clinical samples | 97.14% (Compared with culture standard culture methods) | 91.89% (Compared with culture standard culture methods) | 72 | ||
| MDRTB | Detection of rpoB mutations associated Rifampicin resistance | 84.7% (compared to NNO-LiPA Rif. TB assay) | 100% (compared to NNO-LiPA Rif. TB assay) | 46 | |
| Detection of | 100% ( compared to NNO-LiPA Rif. TB assay) | 100% ( compared to NNO-LiPA Rif. TB assay) | 12 | ||
| Detection of | Analitycal sensitivity of 8.2 pg uL-1 of genomic DNA from clinical samples | n.d. | 5 | ||
| Detection of rpoB and inhA mutations associated with Rifampicin and Isoniazid resistance. Integration with multiplex amplification strategy. Validation with clinical samples | 100% (compared to NNO-LiPA Rif. TB assay) | 100% (compared to NNO-LiPA Rif. TB assay) | 25 |